aibioRockwell Medical regains Nasdaq bid price compliance, matter closed
Tickers RMTI
Nasdaq told Rockwell Medical on July 16, 2026 that the company had regained compliance with the $1.00 minimum bid price, and closed the matter. The 8-K does not give the closing prices behind that finding.
Key facts
- Company
- Rockwell Medical, Inc. (NASDAQ: RMTI)
- News type
- Listings
- Primary source
- Rockwell Medical, Inc. 8-K (2026-07-20)
Rockwell Medical, Inc. (Nasdaq: RMTI) received a written notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC on July 16, 2026. The letter says the company has regained compliance with the minimum $1.00 per share bid price requirement for continued listing on the Nasdaq Capital Market, under Nasdaq Listing Rule 5550(a)(2). Nasdaq considers the compliance matter closed.
Rockwell disclosed the letter in a Form 8-K dated July 20, 2026, filed under Item 8.01, Other Events. The cover page lists the common stock, par value $0.0001 per share, as registered on the Nasdaq Capital Market under the symbol RMTI, and gives the principal executive offices at 30142 S. Wixom Road, Wixom, Michigan. The filing is signed by Chief Executive Officer Mark Strobeck. It furnishes a press release dated July 20, 2026 as Exhibit 99.1, which is the company's own account of the matter.
What the letter does and does not cover
The 8-K does not say which closing prices Nasdaq measured, over what period, or how the stock moved above the threshold. The letter is the only Nasdaq communication the filing describes. The filing says nothing about any other listing standard, so the closed bid price matter should not be read as a statement on the company's full listing status.
The bid price rule looks only at the share price. The loss and cash figures below come from the 10-K, and the 8-K does not connect them to the listing.
The business behind the listing
Rockwell describes itself as a healthcare company that develops, manufactures, commercializes and distributes hemodialysis products for dialysis providers. The 10-K says it is a supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. Hemodialysis is the most common form of end-stage kidney disease treatment, usually given at freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities or in a patient's home. Rockwell says that is a large market opportunity, and that it believes its products are well positioned to meet patients' needs.
The company makes hemodialysis concentrates under current Good Manufacturing Practices at two facilities, in Michigan and Texas, and makes dry acid concentrate mixers in Iowa. Rockwell says it concluded manufacturing at a South Carolina facility in the third quarter of 2025 as part of an effort to streamline operations. It delivers most of its concentrates and mixers to clinics across the United States and abroad, using its own trucks and third-party carriers. CitraPure, Dri-Sate, RenalPure and SteriLyte are registered trademarks of the company. Rockwell was incorporated in Michigan in 1996, re-domiciled to Delaware in 2019 and is based in Wixom, Michigan.
The company's finances
The 10-K filed March 26, 2026 reports a net loss of $5.3 million for 2025, compared with a net loss of $480,000 for 2024. Rockwell used $659,000 in operations in 2025, after providing $4.2 million from operations in 2024. Research and development expense was $0 in 2025 and $19,000 in 2024. Regaining the bid price does not alter the 2025 loss or the cash used that year.
Short-term investments were $14.3 million at the end of 2025, up from $5.9 million at the end of 2024. Cash and cash equivalents were $15.7 million at the end of 2024. Short-term investments rose during a year in which operations used cash. The 8-K itself does not discuss the cash position or the loss.